OTCPK:WILL.F

Stock Analysis Report

Executive Summary

Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally.

Snowflake

Fundamentals

Proven track record with moderate growth potential.


Similar Companies

Share Price & News

How has Demant's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.3%

WILL.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

-29.4%

WILL.F

9.5%

US Medical Equipment

1.1%

US Market

WILL.F underperformed the Medical Equipment industry which returned 9.9% over the past year.

WILL.F underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

WILL.FIndustryMarket
7 Day-5.3%0.7%-0.2%
30 Day-7.5%0.1%2.5%
90 Day-15.2%2.5%1.6%
1 Year-29.4%-29.4%10.4%9.5%3.4%1.1%
3 Year29.2%29.2%69.3%64.1%45.2%35.8%
5 Year-63.2%-63.2%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Demant's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Demant undervalued based on future cash flows and its price relative to the stock market?

0.749%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Demant's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Demant's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Demant is good value based on earnings compared to the US Medical Equipment industry average.

Demant is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Demant is poor value based on expected growth next year.


Price Based on Value of Assets

Demant is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Demant expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

11.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Demant's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).

Demant's earnings are expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).

Demant's revenue growth is expected to exceed the United States of America market average.

Demant's earnings growth is positive but not above the United States of America market average.

Demant's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Demant is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Demant performed over the past 5 years?

7.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Demant's year on year earnings growth rate has been positive over the past 5 years.

Demant's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Demant's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Demant has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Demant used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Demant has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Demant's financial position?


Financial Position Analysis

Demant's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Demant's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Demant's level of debt (95.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (61.8% vs 95.3% today).

Debt is well covered by operating cash flow (24%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 21.9x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is Demant's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Demant's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Demant's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Demant has not reported any payouts.

Unable to verify if Demant's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Demant has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Demant's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Demant's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average board tenure


CEO

Søren Nielsen (49yo)

2.4yrs

Tenure

ø13,400,000

Compensation

Mr. Søren Nielsen has been the Chief Executive Officer and President of William Demant Holding A/S since April 1, 2017 and has been its Member of Executive Board since September 1, 2015 and President of Ot ...


CEO Compensation Analysis

Søren's remuneration is lower than average for companies of similar size in United States of America.

Søren's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

3.2yrs

Average Tenure

55yo

Average Age

The tenure for the Demant board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Søren Nielsen (49yo)

    CEO, President & Member of Executive Board

    • Tenure: 2.4yrs
    • Compensation: ø13.40m
  • Søren Andersson (42yo)

    Vice President of Investor Relations

    • Tenure: 0yrs
  • René Schneider (46yo)

    CFO & Member of Executive Board

    • Tenure: 4yrs
    • Compensation: ø6.00m
  • Trine Kromann-Mikkelsen

    Vice President of Corporate Communication & Relations

    • Tenure: 0yrs
  • Jes Olsen

    President of Oticon Medical

    • Tenure: 0yrs

Board Members

  • Niels Jacobsen (62yo)

    Deputy Chairman

    • Tenure: 2.4yrs
  • Niels Christiansen (53yo)

    Chairman

    • Tenure: 2.7yrs
  • Lars Rasmussen (60yo)

    Director

    • Tenure: 3.7yrs
  • Peter Foss (63yo)

    Director

    • Tenure: 12.7yrs
  • Jørgen Nielsen (57yo)

    Director

    • Tenure: 2.6yrs
  • Benedikte Leroy (49yo)

    Director

    • Tenure: 5.7yrs
  • Thomas Duer (46yo)

    Director

    • Tenure: 4.7yrs
  • Casper Jensen (40yo)

    Director

    • Tenure: 0.7yrs

Company Information

Demant A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Demant A/S
  • Ticker: WILL.F
  • Exchange: OTCPK
  • Founded: 1904
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ø46.065b
  • Listing Market Cap: ø6.817b
  • Shares outstanding: 245.29m
  • Website: https://www.demant.com

Number of Employees


Location

  • Demant A/S
  • Kongebakken 9
  • Smørum
  • 2765
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
WILL.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDMay 1995
DEMANTCPSE (OMX Nordic Exchange Copenhagen)YesShare CapitalDKDKKMay 1995
WDH1DB (Deutsche Boerse AG)YesShare CapitalDEEURMay 1995
0RGTLSE (London Stock Exchange)YesShare CapitalGBDKKMay 1995
WILY.YOTCPK (Pink Sheets LLC)UNSPONSORED ADSUSUSDNov 2008

Biography

Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally. Its products ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:27
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.